Related Experiment Videos
Antisense BAG-1 sensitizes HeLa cells to apoptosis by multiple pathways
Jieying Xiong1, Jun Chen, Garry Chernenko
1Memorial University of Newfoundland, Basic Medical Sciences, 300 Prince Philip Dr., St. John's, NL, Canada A1B 3V6.
Biochemical and Biophysical Research Communications
|December 19, 2003
Summary
BAG-1 protein inhibits anti-cancer drug-induced apoptosis. Reducing BAG-1 enhances apoptosis by affecting p53, Bcl-2/Bax ratio, and cytochrome c release, offering new therapeutic targets.
Area of Science:
- Molecular Biology
- Cell Biology
- Cancer Research
Background:
- BAG-1 (Bcl-2-associated athanogene 1) is implicated in cell survival and apoptosis regulation.
- Understanding BAG-1's role in drug-induced apoptosis is crucial for developing effective cancer therapies.
Purpose of the Study:
- To elucidate the mechanism of action of BAG-1 in mediating resistance to anti-cancer drugs.
- To investigate the role of BAG-1 in regulating apoptosis pathways.
Main Methods:
- Construction of an antisense BAG-1 vector and establishment of a stably transfected HeLa cell line with reduced BAG-1 expression.
- Treatment with various anti-cancer drugs (staurosporine, paclitaxel, all-trans retinoic acid, N-(4-hydroxyphenyl) retinamide) and assessment of apoptosis, cell viability, and protein expression (p53, Bcl-2, Bax, cytochrome c).
Main Results:
- Reduced BAG-1 expression significantly enhanced drug-induced apoptosis and decreased cell viability.
- Downregulation of BAG-1 led to increased p53 expression and decreased Bcl-2 and Bax levels.
- Underexpression of BAG-1 resulted in reduced cytosolic cytochrome c levels, with differential effects on drug-mediated mitochondrial release.
Conclusions:
- BAG-1 acts as an inhibitor of anti-cancer drug-induced apoptosis.
- The mechanism involves modulation of the mitochondrial Bcl-2/Bax ratio, p53, and differential cytochrome c release pathways.
- Targeting BAG-1 may represent a viable strategy to overcome drug resistance in cancer treatment.